Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies
Steven T. Bird(Brigham and Women's Hospital), Kate Gelperin(United States Food and Drug Administration), Peter Waldron(Center for Drug Evaluation and Research), Jacqueline M. Major(United States Food and Drug Administration), Elizabeth L Durmowicz(United States Food and Drug Administration), Ólanrewaju O. Okusanya, Fang Tian(United States Food and Drug Administration), Richard S. Swain(United States Food and Drug Administration), Mona Khurana(United States Food and Drug Administration), Yong Ma(United States Food and Drug Administration)
Cited by 21
Related Papers
Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis
|Canadian Medical Association Journal|2012|120
Isotretinoin and Risk for Inflammatory Bowel Disease
|JAMA Dermatology|2013|93
Risk of acute kidney injury associated with the use of fluoroquinolones
|Canadian Medical Association Journal|2013|89